Company Q1 Revenue of $3.91B Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $3.91B, consensus $3.85B. "Our year is off to an encouraging start, as our continued efforts to strengthen the business and sharpen execution resulted in delivering net and organic sales growth for the second consecutive quarter, along with meaningful year-over-year improvement in gross margin, operating margin, and EPS," said Kirk Perry, Chief Executive Officer. "We remain confident in our ability to navigate ongoing macro uncertainty, as we accelerate our organization and business transformation through our new strategic plans and work toward completing our value-creating combination with Kimberly-Clark in the second half of this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 18.070
Low
17.00
Averages
18.86
High
23.00
Current: 18.070
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SpaceX Sets Record with $75 Billion IPO, Valued at $1.77 Trillion
- Record Financing: SpaceX is set to conduct its IPO on June 12, aiming to raise up to $75 billion with a valuation of $1.77 trillion, marking the largest IPO in history, although this high valuation poses downside risks.
- Oversubscription Details: The IPO shares are priced at $135 each, with demand exceeding the available shares by a factor of four, indicating strong investor interest in SpaceX, but this could lead to price volatility in the short term.
- Market Performance Expectations: Historical data shows that IPO stocks have averaged a 25% gain on their first trading day over the past decade, but large IPOs typically experience significant declines in their first year, and SpaceX may face a similar fate.
- Competitive Market Analysis: SpaceX's P/S ratio stands at 92, significantly higher than Palantir's 63, indicating an extremely high valuation, and large IPO stocks have historically underperformed, suggesting a potential sharp decline in the following year.
See More
SpaceX Sets Record for Largest IPO in History
- IPO Pricing and Valuation: SpaceX's IPO is priced at $135 per share, leading to an initial market capitalization of $1.77 trillion, marking the largest IPO in history; however, this valuation results in a price-to-sales ratio of 92, indicating significant downside risk given its $19.3 billion in annual revenue.
- Strong Market Demand: The IPO has seen exceptionally strong demand, with investment banks reporting that SpaceX's stock is four times oversubscribed, reflecting high market expectations for future growth, yet historical trends show that large IPOs often perform poorly in their first year.
- Integrated Business Model: SpaceX's unique vertical integration combines launch, connectivity, and computing technologies, positioning it to capture a significant share of the $28.5 trillion market, particularly in AI infrastructure and Starlink satellite internet services.
- Historical Performance Warning: Despite the hype surrounding SpaceX's IPO, historical data indicates that the ten largest IPO stocks have averaged a 21% decline in their first year, and their long-term returns typically lag behind the S&P 500, suggesting investors should proceed with caution.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
SpaceX Set to Launch Largest IPO in History
- Record IPO Valuation: SpaceX's IPO is priced at $135 per share, leading to an expected market capitalization of $1.77 trillion, marking the largest IPO in history; however, its valuation exceeds 90 times sales, indicating significant overvaluation risks.
- Historical Performance Warning: Historical data shows that the 10 largest U.S. IPO stocks have underperformed the S&P 500 by 96 percentage points since their listings, suggesting that investors might be better off investing in an S&P 500 index fund rather than participating in SpaceX's IPO.
- Strong Market Demand: While investment banks report immense demand for SpaceX's IPO, Morningstar analysts estimate its fair value at only $780 billion, implying a 56% downside from the IPO valuation of $1.77 trillion, necessitating caution among investors.
- Investor Strategy Recommendation: Although SpaceX's IPO may initially perform well, historical trends indicate it may underperform the S&P 500 in the long run, prompting a recommendation for investors to consider the Vanguard S&P 500 ETF for more stable returns.
See More
SpaceX to Go Public on June 12, Setting Record for Largest IPO
- IPO Pricing and Valuation: SpaceX has priced its IPO at $135 per share, leading to an initial market capitalization of $1.77 trillion, making it the largest IPO on record, although its valuation at 92 times sales indicates significant overvaluation risks.
- Market Demand and Performance Outlook: Underwriters report immense demand for SpaceX shares, yet historical data suggests the company may underperform the S&P 500 in the long run, indicating that investors might be better off investing in an S&P 500 index fund instead.
- Historical Performance Comparison: Data shows that over 1,100 companies listed since 2016 have averaged a 25% increase on their first trading day, but larger IPOs often face selling pressure as lock-up periods expire, a trend SpaceX may also experience.
- Investment Advice and Risks: While SpaceX's market value could potentially soar to $5 trillion post-IPO, Morningstar analysts estimate its fair value at $780 billion, suggesting a 56% downside from its IPO valuation, advising investors to remain cautious.
See More
SpaceX Sets Record with $75 Billion IPO, Valued at $1.77 Trillion
- Record Financing: SpaceX is set to conduct its IPO on June 12, aiming to raise up to $75 billion with a valuation of $1.77 trillion, marking the largest IPO in history, although this high valuation poses downside risks.
- Oversubscription Details: The IPO shares are priced at $135 each, with demand exceeding the available shares by a factor of four, indicating strong investor interest in SpaceX, but this could lead to price volatility in the short term.
- Market Performance Expectations: Historical data shows that IPO stocks have averaged a 25% gain on their first trading day over the past decade, but large IPOs typically experience significant declines in their first year, and SpaceX may face a similar fate.
- Competitive Market Analysis: SpaceX's P/S ratio stands at 92, significantly higher than Palantir's 63, indicating an extremely high valuation, and large IPO stocks have historically underperformed, suggesting a potential sharp decline in the following year.
See More
SpaceX Sets Record for Largest IPO in History
- IPO Pricing and Valuation: SpaceX's IPO is priced at $135 per share, leading to an initial market capitalization of $1.77 trillion, marking the largest IPO in history; however, this valuation results in a price-to-sales ratio of 92, indicating significant downside risk given its $19.3 billion in annual revenue.
- Strong Market Demand: The IPO has seen exceptionally strong demand, with investment banks reporting that SpaceX's stock is four times oversubscribed, reflecting high market expectations for future growth, yet historical trends show that large IPOs often perform poorly in their first year.
- Integrated Business Model: SpaceX's unique vertical integration combines launch, connectivity, and computing technologies, positioning it to capture a significant share of the $28.5 trillion market, particularly in AI infrastructure and Starlink satellite internet services.
- Historical Performance Warning: Despite the hype surrounding SpaceX's IPO, historical data indicates that the ten largest IPO stocks have averaged a 21% decline in their first year, and their long-term returns typically lag behind the S&P 500, suggesting investors should proceed with caution.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
SpaceX Set to Launch Largest IPO in History
- Record IPO Valuation: SpaceX's IPO is priced at $135 per share, leading to an expected market capitalization of $1.77 trillion, marking the largest IPO in history; however, its valuation exceeds 90 times sales, indicating significant overvaluation risks.
- Historical Performance Warning: Historical data shows that the 10 largest U.S. IPO stocks have underperformed the S&P 500 by 96 percentage points since their listings, suggesting that investors might be better off investing in an S&P 500 index fund rather than participating in SpaceX's IPO.
- Strong Market Demand: While investment banks report immense demand for SpaceX's IPO, Morningstar analysts estimate its fair value at only $780 billion, implying a 56% downside from the IPO valuation of $1.77 trillion, necessitating caution among investors.
- Investor Strategy Recommendation: Although SpaceX's IPO may initially perform well, historical trends indicate it may underperform the S&P 500 in the long run, prompting a recommendation for investors to consider the Vanguard S&P 500 ETF for more stable returns.
See More
SpaceX to Go Public on June 12, Setting Record for Largest IPO
- IPO Pricing and Valuation: SpaceX has priced its IPO at $135 per share, leading to an initial market capitalization of $1.77 trillion, making it the largest IPO on record, although its valuation at 92 times sales indicates significant overvaluation risks.
- Market Demand and Performance Outlook: Underwriters report immense demand for SpaceX shares, yet historical data suggests the company may underperform the S&P 500 in the long run, indicating that investors might be better off investing in an S&P 500 index fund instead.
- Historical Performance Comparison: Data shows that over 1,100 companies listed since 2016 have averaged a 25% increase on their first trading day, but larger IPOs often face selling pressure as lock-up periods expire, a trend SpaceX may also experience.
- Investment Advice and Risks: While SpaceX's market value could potentially soar to $5 trillion post-IPO, Morningstar analysts estimate its fair value at $780 billion, suggesting a 56% downside from its IPO valuation, advising investors to remain cautious.
See More
